AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06755502 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Garlic oil
Description: garlic oil mixed with zinc oxid powder, as root canal filling material
Study NCT06755502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Hydroxide, Iodoform, paste
Description: Metapex as root canal filling materials
Study NCT06755008 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bronchial fibroscopy
Description: 2 bronchial biopsies will be taken during bronchial fibroscopy
Study NCT06755008 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchial fibroscopy
Description: 2 bronchial biopsies will be taken during bronchial fibroscopy
Study NCT06753890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Changkang granules
Description: 7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
Study NCT06753890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Changkang Granules placebo
Description: 7.5g/bag, 1 bag per dose, 2 doses per day, oral，4 consecutive weeks.
Study NCT06755320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation (MV)
Description: Mechanical ventilation APRV mode ( Airway Pressure Release Ventilation )
Study NCT06755320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: mechanical ventilation (MV)
Description: Mechanical Ventilation in BiPAP mode (Bi-Level Positive Airway Pressure Ventilation )
Study NCT06753318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The assistance of the Joint-AI model
Description: Predictions given by the Joint-AI model will be provided to the endoscopists during their diagnosis
Study NCT06753318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The assistance of the interpretable Joint-AI model
Description: Predictions given by the Joint-AI model and the results of the interpretability analysis will be provided to the endoscopists during their diagnosis
Study NCT06752642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant overdenture
Description: patients received implant overdenture
Study NCT06752759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebulized ketamine
Description: The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
Study NCT06752759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nebulized ketamine
Description: The formulation of the study drug is administered via nebulizer in which the participants inhales the study drug. The dosage is calculated by body weight (1.5mg/kg).
Study NCT06756178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol Group 1
Description: Postoperative Use:~Bolus: 10-20 mg intravenously as needed for sedation initiation. Continuous infusion: 0.3-0.5 mg/kg/hour to maintain light sedation adjusted based on clinical response.
Study NCT06756178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Intervention
Description: Postoperative Use:~Initial bolus: 5 mg intravenously upon ICU arrival. Continuous infusion: 0.2-0.3 mg/kg/hour to maintain light sedation with a maximum dose of 0.8 mg/kg/hour.~Rescue sedation with propofol or midazolam will be allowed if patients become agitated or if Remimazolam is ineffective in maintaining target sedation.
Study NCT06756178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Intervention
Description: Postoperative Use:~Loading dose: 0.5-1 μg/kg over 10-20 minutes after ICU arrival. Continuous infusion: 0.2-0.7 μg/kg/hour for sedation maintenance, adjusted as needed to maintain light sedation.~Rescue sedation with propofol or midazolam will be administered if Dexmedetomidine fails to maintain adequate sedation or if patients become agitated.
Study NCT06753578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT); Quality of Life (QOL); Mild Cognitive Impairment (MCI); cognitive function; elderly; psychological flexibility.
Study NCT06753578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care
Study NCT06752278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: Pilocarpine is a muscarinic agonist
Study NCT06752278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artificial tears
Description: artificial tears used for the treatment of Dry eye
Study NCT06755047 — intervention group
Intervention type: RADIATION
Intervention: 3D Ultrasound
Description: 3D placental volume and vascular indices
Study NCT06755047 — intervention group
Intervention type: RADIATION
Intervention: 2D ultrasound
Description: 2D placental criteria of invasion and color Doppler
Study NCT06752161 — intervention group
Intervention type: OTHER
Intervention: Urine analysis
Description: Urine analysis and culture for Screening and diagnostic tools for UTI in pregnant women
Study NCT06752668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORX750
Description: ORX750 capsule.
Study NCT06752668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ORX750 matching placebo capsule.
Study NCT06091800 — intervention group
Intervention type: OTHER
Intervention: biochemical analysis
Description: GCF and serum samples were collected from the participants for biochemical analysis.
Study NCT06417606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib（oral，12mg once daily if body weight ≥60Kg; Body weight \< 60Kg, 8mg/ day）； Adebrelimab（intravenous drip，1200mg once every 3 weeks）； GEMOX（intravenous drip，Gemcitabine 1000mg/m2, 2 times every 3 weeks d1+d8; intravenous drip，Oxaliplatin, 100mg/m2, was given every 3 weeks）
Study NCT06546397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol/dydrogesterone tablets
Description: The medication group began taking 17β-estradiol/dydrogesterone tablets orally for 28 days starting from the first day after induced abortion surgery (taking 2mg of 17β-estradiol orally once a day for the first 14 days, and then taking 2mg of 17β-estradiol + 10mg of dydrogesterone tablets orally once a day for the next 14 days). The blank control group did not take any medication.
Study NCT05250349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic echocardiography with standard measurements
Study NCT05250349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler sonography
Description: Transcarotid and transcranial Doppler sonography
Study NCT05250349 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA)
Study NCT05718388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy exercises
Description: For two consecutive months, the children in control group underwent a physiotherapy program for 60min/ three sessions each week: it was based mainly on the neurodevelopment technique, directed toward inhibiting abnormal muscle tone facilitating normal patterns of postural control and hand functions training program
Study NCT05718388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic training
Description: Children in study group received the same program given to control group (A) in addition to isokinetic resistance training of the less affected upper limb for shoulder abductors in concentric mode at the angular velocity of 180 degree/ second under full supervision on the Biodex isokinetic dynamometer three times per week for 8 weeks, making a total of 24 training sessions. Each child was trained in the seated position with the similar precaution of the testing protocol.
Study NCT04854512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin DR
Description: Delay-Release Metformin
Study NCT04854512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin IR
Description: Immediate Release Metformin
Study NCT04854512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin DR Placebo
Description: Metformin DR Placebo
Study NCT04854512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin DR Placebo
Description: Metformin DR Placebo
Study NCT04854512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR placebo
Description: Metformin IR placebo
Study NCT04854512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin IR placebo
Description: Metformin IR placebo
Study NCT05687396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality designed as cycling in the forest
Study NCT05687396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional pulmonary rehabilitation
Description: pulmonary rehabilitation
Study NCT05033717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Flossing Technique
Description: Subjects will receive tissue-flossing intervention on bicep muscle for 30 sec to 2 min with an occlusion pressure of 100 mmHg.~After removal of flossing, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 rep, 4 sets for a single day and 3 days per week for 2 weeks in total.
Study NCT05033717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static Stretching Technique
Description: Subjects will perform passive static stretching exercises of bicep muscle. Each stretch will last for 30 sec at 100% of stretch intensity with 4 reps for each, 1 set per day and 3 days per week for total duration of two weeks.~After the application of static stretch, participants will perform bicep strengthening exercises at an intensity of 30% of 1 RM with 6-8 reps, 4 sets for a single day and 3 days per week for 2 weeks in total.
Study NCT05579470 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIATx
Description: For each country, the learning collaborative will be comprised of a Chief Narcologist from each region where the investigators will initially train them and the coaches using all the tools from the NIATx Academy (2-3-day training). The national coach for each country will receive ongoing and in-depth coaching from a US-based super coach. A nationwide Nominal Group Technique (NGT) will be conducted to assess barriers and potential targets to guide decision-making about changes. At the end of the initial meeting, each Chief Narcologist (CN) will be able to identify a change target for Plan, Do, Study, Act (PDSA) (entry, retention) and create a Change Project Form to state what will be done (e.g. flowcharting), who is involved (team), what are the measures and timeframe (\<4 weeks).
Study NCT06753409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Processed electroencephalography (pEEG) Guided General Anesthesia
Description: Processed electroencephalography (pEEG) can guide the optimization of anesthesia depth, potentially preventing overly deep anesthesia and, in turn, reducing the incidence of IOH and the need for vasopressors .~Depth of anesthesia will be managed based on pEEG monitoring using Entropy with a target range of 40-60.
Study NCT05484375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine plus toripalimab
Description: Capecitabine tablet: 650mg/m2, orally, twice a day, d1-d21, every 3 weeks Toripalimab: 240mg, intravenous drip, d1, every 3 weeks
Study NCT05472610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BZ019
Description: A treatment program will include lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by single-dose of BZ019 administered intravenously (IV).
Study NCT06413628 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: screw tapered appliance
Description: The appliance was digitally designed by solid works programs for 3rd CAD design software to obtain the STL file format. The virtual design of was approved. The printerwas loaded with material of 3D-printed denture base. The appliance was printed.
Study NCT05708118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiographic assessment.
Description: Patients will be contacted to carry out an echocardiography at least 90 days after surgery. Measurements will be taken for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta. Aortic valve will be assessed as well.
Study NCT05708118 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed-tomography assessment
Description: All enrolled patients will undergo a multislice CT scan (retrospectively ECG-gated, whenever possible) with standard contrast medium injection protocol of nonionic contrast agent. All post-surgery controls will be performed at least 90 days after surgery. All CT datasets will be analysed on a dedicated workstation for the qualitative and quantitative assessment of the aortic root including measurements for aortic annulus, sinuses of Valsalva, sino-tubular junction, tubular ascending aorta.
Study NCT04694599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow oxygen
Description: Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
Study NCT04694599 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen
Description: Low flow oxygen delivered via nasal prong or facial mask. The flow rate is adjusted according to oxygen saturation of the patient.
Study NCT04409236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit2Heal
Description: Use Quit2Heal app
Study NCT04409236 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitGuide
Description: Use QuitGuide app
Study NCT04409236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT04409236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05705440 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RSVPreF3 vaccine
Description: No intervention is administered in this extension study. Participants received the RSVPreF3 vaccine during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of RSVPreF3 vaccine except in RSV MAT-011 study, where some participants received a second dose as well.
Study NCT05705440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No intervention is administered in this extension study. Participants received any control (placebo, Tdap or influenza vaccine) during the prior RSV MAT studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) according to the vaccination schedule specific to each study. In all prior RSV MAT studies, participants received one dose of any control (placebo, Tdap or influenza vaccine).
Study NCT06753409 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-pEEG-Guided General Anesthesia (with blinded pEEG monitoring)
Description: Depth of anesthesia will be managed based on clinical judgment, informed by clinical perception and vital signs.
Study NCT06751888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled CO2 delivery
Description: The use of a controlled CO2 delivery offers a straightforward way to increase arterial CO2. Controlled CO2 inhalation may offer a novel hemodynamic therapy for patients with Neurogenic Orthostatic Hypotension
Study NCT06751888 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Controlled CO2 delivery (Sham)
Description: For this intervention, we will be using this device set at 0% CO2 for our sham comparison.
Study NCT06752317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: patients will receive intrathecal dexamethasone 8 mg in 3 ml volume.
Study NCT06752317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patients will receive intrathecal dexmedetomidine 0.5 µg/kg in 3 ml volume.
Study NCT06754839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous left ventricular assist device(Ventiflow LP)
Description: The PCI will be completed with the support of percutaneous left ventricular assist device(Ventiflow LP).
Study NCT06754839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VA-ECMO
Description: The PCI will be completed with the support of Veno-arterial extracorporeal membrane oxygenation (VA-ECMO).
Study NCT06756035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-95
Description: Weekly IV dosing
Study NCT06752174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sIPV+bOPV
Description: 2+1 sequential immunization program (sIPV-sIPV-bOPV)
Study NCT06752174 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: wIPV+bOPV
Description: 2+1 sequential immunization program (wIPV-wIPV-bOPV)
Study NCT06752382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.
Study NCT06756191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy group
Description: Liposomal amphotericin B (AmBisome®) combination with Isavuconazole
Study NCT06756191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Amphotericin B
Description: Liposomal amphotericin B (AmBisome®) alone
Study NCT06755866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The application value of MRI 4D Free Breathing DCE-MRI in the treatment of esophageal cancer
Description: Chest MRI scan outside of standard treatment options
Study NCT06751940 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Conventional second-line therapy
Description: Conventional second-line therapy includes chemotherapy, targeted cancer drugs, and/or PD-1 inhibitors.The chemotherapy drugs, dosage and treatment cycle are determined by the subject's attending physician based on the subject's specific conditions. The medication, dosage and treatment cycle of targeted cancer drugs will be determined by the subject's attending physician based on the subject's specific circumstances. The PD-1 inhibitor treatment cycle is 3 weeks, and the drug is administered by intravenous infusion on the first day (D1) of each treatment cycle. The dosage is based on the instructions.
Study NCT06751940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoantigen-loaded DC vaccine
Description: The treatment with personalized tumor neoantigen-loaded DC vaccine is divided into two periods: the primary phase and the boost phase. The primary phase consists of 6 treatments, with the first 3 treatments spaced one week apart and the subsequent 3 treatments spaced two weeks apart. Vaccine will be administrated on the fourth day (D4) of that week. The boost phase consists of 4 treatments, each spaced three weeks apart. Vaccine will be administrated on the fourth day (D4) of that week.
Study NCT06752655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curcumin with photodynamic thearpy
Description: root canals will irrigated with final irrigation procedure: curcumin+photodynamic therapy. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
Study NCT06752655 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: root canals will irrigated with routine root canal final irrigation with NaOCl and EDTA. The teeth will be isolated with a rubber dam, and an access cavity will be created. After root canal preparation, the final irrigation procedure will be performed. Root canal treatments will be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.
Study NCT06753006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurorehabilitation simulator
Description: The participant must complete a mental task - imagine the movement of his arm. If successful, the robotic simulator moves the paralyzed limb.
Study NCT06753006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard course
Description: The participant receives a standard course of intervention as prescribed by the attending physician in accordance
Study NCT06753006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard course
Description: The participant receives a standard course of intervention as prescribed by the attending physician in accordance
Study NCT06754020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability,HRV - ANSWatch
Description: Please have the participant lie down and rest for 10 minutes, and remove any metallic items from their body. Next, put on the wrist-worn monitor, and avoid moving during the monitoring process. The device will emit a sound when the monitoring session is complete.
Study NCT06754020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine Tongue Imaging
Description: Use a camera to capture images of the tongue, and then have a Traditional Chinese Medicine (TCM) practitioner perform the diagnosis based on these images.
Study NCT06751472 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VPS (Verbal Pain Score)
Description: İt is a pain intensity determination system based on the system where there person tells a point between 0=(no pain) 10=( unbearable pain) and to describe their pain